Standard BioTools Inc. (LAB) News

Standard BioTools Inc. (LAB): $1.36

-0.07 (-4.90%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter LAB News Items

LAB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

LAB News Highlights

  • For LAB, its 30 day story count is now at 5.
  • Over the past 21 days, the trend for LAB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • NOV are the most mentioned tickers in articles about LAB.

Latest LAB News From Around the Web

Below are the latest news stories about STANDARD BIOTOOLS INC that investors may wish to consider to help them evaluate LAB as an investment opportunity.

Standard BioTools Authorizes up to $20 Million of Share Repurchases

SOUTH SAN FRANCISCO, Calif., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that its board of directors has authorized the repurchase of up to $20 million of shares of its common stock in the open market or in negotiated transactions through December 31, 2023. The repurchases are expected to be made from cash on hand, which the Company’s board believes is an effective

Yahoo | November 28, 2022

Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of November 20, 2022, under the Standard BioTools Inc. 2022 Inducement Equity Incentive Plan (Plan), as a material inducement to ten individuals entering into employment with Standard BioTools. The equity awards were approved in accordanc

Yahoo | November 22, 2022

Standard BioTools Third Quarter 2022 Earnings: US$0.37 loss per share (vs US$0.18 loss in 3Q 2021)

Standard BioTools ( NASDAQ:LAB ) Third Quarter 2022 Results Key Financial Results Revenue: US$25.6m (down 10.0% from 3Q...

Yahoo | November 11, 2022

Standard BioTools Announces Third Quarter 2022 Financial Results

Third quarter core product and services revenue increase of 30% sequentially to $24.8 million First phase of restructuring program improves operating margin by 600 to 800 basis points, or $8.0 million net on an annualized basis Reiterate stated goal of 700 to 1000 basis point non-GAAP product and service gross margin improvement to 65-68% by year end 2023, driven by lean transformation, volume growth and value selling On track to achieve positive free cash flow by year-end 2024 Cash, cash equiva

Yahoo | November 8, 2022

Standard BioTools and Visiopharm Announce Partnership for the Development of Complete Image Analysis Solutions to be Packaged With Hyperion and Hyperion+ Imaging Systems

Seamlessly linking the Standard BioTools portfolio of Imaging Mass Cytometry (IMC) systems with Visiopharm AI-driven software for phenotyping cells in high-plex imagingSOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – and Visiopharm® today announced a collaboration to pair the company’s Hyperion™ and Hyperion+™ Imaging Systems with Visiopharm Phenoplex™ anal

Yahoo | November 7, 2022

Standard BioTools Announces Conference Call and Webcast of Third Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022, after the close of the market. The Company’s management will host a conference call and webcast at 2:00 p.m. PT, 5:00 p.m. ET, on November 8, 2022, to discuss third quarter 2022 financial results and operati

Yahoo | October 25, 2022

Ascendas Genomics Receives NMPA Approval for Use of Standard BioTools Microfluidics Technology to Advance the Development of Molecular Diagnostics in China

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that Ascendas Genomics has received approval from the National Medical Products Administration (NMPA) of China for use of the company’s Biomark™ family of systems and its Juno™ system in NMPA molecular diagnostics services, enabling an important advance for microfluidics technology in the cou

Yahoo | October 13, 2022

Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform

The microfluidics-based system accommodates scalable throughputs to address specific and evolving project needsSOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced the launch of the X9™ Real-Time PCR System, an innovative high-capacity genomics instrument offering superior efficiency. X9 enables high data output with more than 9,000 individual

Yahoo | October 6, 2022

Is Standard BioTools (NASDAQ:LAB) Using Debt In A Risky Way?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Yahoo | August 14, 2022

Standard BioTools Announces Second Quarter 2022 Financial Results and Provides Strategic Update

Second quarter revenue of $18.8 million Completed $250 million strategic cash infusion from Casdin Capital and Viking Global Upgraded management team and added board members to bring significant sector and operational expertise to the company Commenced restructuring program with the explicit goal of returning core business to growth, raising gross margins by approximately 7-10% and substantially reducing operating cash burn Cash, cash equivalents, and short-term investments expected to provide s

Yahoo | August 8, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6676 seconds.